Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RAGE

RAGE

Brief Information

Name:Advanced glycosylation end product-specific receptor
Target Synonym:Receptor for advanced glycosylation end products,AGER,Advanced Glycosylation End-Product Specific Receptor,RAGE,Receptor For Advanced Glycation End-Products Variant 20,Receptor For Advanced Glycation End-Products,RAGE Isoform NtRAGE-Delta,RAGE Isoform SRA
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CHEK-ATP156 Human HEK293/Human RAGE Stable Cell Line
ACRO Quality

Synonym Name

AGER,RAGE

Background

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

Clinical and Translational Updates

Related Molecule

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message